-
Sodium Oxamate in Cancer Metabolism Research
2026-09-23
Use Sodium Oxamate to test whether LDH-A-linked lactate production contributes to metabolic phenotypes and radiation responses—not as a stand-alone readout of lactylation. This workflow pairs dose finding with lactate, viability, and DNA-repair measurements to distinguish metabolic effects from nonspecific toxicity.
-
Salinomycin: Ion Homeostasis in HCC Assays
2026-09-23
Salinomycin is a polyether ionophore antibiotic with experimental activity in hepatocellular carcinoma models. This article presents an assay-centered framework linking ion transport, Wnt/β-catenin signaling, apoptosis, and toxicity-aware interpretation.
-
Catalpol Rewires Glycolysis in Liver Fibrosis
2026-09-22
A 2024 Phytomedicine study identifies a mechanistic link between catalpol, EphA2/FAK/Src signaling, and aerobic glycolysis in activated hepatic stellate cells. Its combination of mouse, cell-based, biochemical, and target-engagement experiments suggests that suppressing glycolytic reprogramming may be an important route for limiting fibrogenesis, while also defining the boundaries of evidence from toxin-induced and in vitro models.
-
Bifendate (DDB): Reliable Cell Assay Design
2026-09-22
Learn how Bifendate (DDB), SKU BA1823, can be incorporated into cell viability, proliferation, cytotoxicity, and autophagy workflows with controlled formulation and evidence-based interpretation. This guide addresses solubility, exposure design, lipid-related confounding, and practical vendor selection.
-
PSI-7977: Mechanism and Assay Context
2026-09-21
PSI-7977 is an HCV NS5B-targeting nucleotide prodrug with a mechanism distinct from BAP1-regulated disulfidptosis. This article explains how to use that distinction to design better controls, interpret NADPH and cystine biology, and avoid unsupported mechanistic conclusions.
-
PAD4-IN-2 TFA: Targeting the Tumor NET Axis
2026-09-21
PAD4-IN-2 TFA, also known as Compound 5i TFA, offers a tumor-oriented strategy for interrogating the PAD4–H3cit–NET axis. This thought-leadership analysis connects phenylboronic acid-mediated uptake with mechanistic assays, metastasis models, immune-microenvironment profiling, and translational decision-making.
-
Silymarin Assay Design: From Mixture to Mechanism
2026-09-20
Silymarin is a chemically complex milk thistle extract whose biological interpretation depends on composition, solvent, and assay design. This guide connects flavonolignan chemistry with practical controls for oxidative stress, cancer, metabolic, and antiviral research.
-
Bifendate (DDB) Experimental Workflows
2026-09-19
Build reproducible liver-injury, lipid-accumulation, and autophagy experiments around Bifendate (DDB), with solvent-aware dosing and orthogonal readouts. The workflow also incorporates multiomics-guided target validation and CYP3A4 interaction controls for stronger translational interpretation.
-
Parthenolide, ROS, and Apoptosis in Lymphoid Malignancies
2026-09-18
A 2023 study mapped parthenolide responses across multiple lymphoid malignancy models by combining resazurin metabolic profiling with flow-cytometric, mitochondrial, oxidative-stress, and gene-expression measurements. Its findings support a cell-line-dependent, ROS-associated apoptotic response and illustrate why metabolic viability results should be interpreted alongside orthogonal mechanistic endpoints.
-
ALOX5, Ferroptosis, and CRSwNP Barrier Dysfunction
2026-09-18
Huang et al. integrated transcriptomic analysis, network biology, machine learning, and experimental validation to identify ALOX5 as a ferroptosis-associated marker linked to epithelial barrier injury in CRSwNP. The study connects molecular discovery with tissue and primary-cell evidence, while also defining important limits for causal interpretation and clinical translation.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-09-17
Shiota and colleagues developed a dCAS9-based transcriptional screen that identified structurally diverse HDAC inhibitors as suppressors of BRD4-NUT activity. The study connects HDAC inhibition with megadomain remodeling, differentiation, growth suppression, and improved bromodomain-inhibitor responses in NUT carcinoma models.
-
Cyanine 5-dCTP and the Next EOS Design Logic
2026-09-17
Enzymatic oligonucleotide synthesis is moving from a chemistry problem toward an interface-engineering problem. This article examines how Cyanine 5-dCTP can add a functional optical readout to highly ordered DNA frameworks, while outlining practical validation, translational boundaries, and workflow strategy.
-
Grazoprevir/Elbasvir Therapy for HCV: Evidence Review
2026-09-16
The reference review explains why combining grazoprevir, an NS3/4A protease inhibitor, with elbasvir, an NS5A inhibitor, enabled effective interferon-free treatment across important HCV populations. Its main practical contribution is an integrated interpretation of virologic efficacy, resistance, safety, pharmacology, and special-population evidence rather than a new clinical trial.
-
Asunaprevir: HCV Research Workflows
2026-09-16
Build a practical assay cascade around Asunaprevir (BMS-650032), from NS3/4A protease target engagement to cell-based HCV RNA replication inhibition. The guide also adapts a chemical-screening logic from a NUT carcinoma study while clearly separating transferable workflow design from unsupported cross-domain mechanisms.
-
Podophyllotoxin: Reading Autophagy Signals in HCC
2026-09-15
Podophyllotoxin is a powerful cell cycle arrest agent for cancer biology, but its effects on autophagy and apoptosis require careful interpretation. This guide uses hepatocellular carcinoma research to distinguish microtubule stress, autophagic flux, and cell death while translating product specifications into better assay decisions.